Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 4:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,755 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Major Depressive Disorders Clear all
Terminated No phase listed Observational

PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder

NCT04353921
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
No intervention will be administered as part of this study.
Other
Lead sponsor
Usona Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lauderhill, Florida
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 28, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

Ketamine for the Treatment of Opioid Use Disorder and Depression

NCT04177706
View directory record Official record
Conditions
Depression, Opioid-use Disorder, Opioid Abuse
Interventions
Ketamine Hydrochloride, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 28, 2026, 4:56 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Interactive Voice-Based Administration of the PHQ-9

NCT04609267
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
PHQ-9 - Mirror format
Diagnostic Test
Lead sponsor
Oklahoma State University Center for Health Sciences
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 28, 2026, 4:56 PM EDT
Recruiting No phase listed Observational

ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1

NCT07528014
View directory record Official record
Conditions
Depressed Mood
Interventions
Not listed
Lead sponsor
Salma Health, Inc.
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
2
States / cities
La Jolla, California • Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 28, 2026, 4:56 PM EDT
Recruiting Phase 3 Interventional

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

NCT06830044
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Milsaperidone, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
29
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Garden Grove, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 28, 2026, 4:56 PM EDT
Completed Phase 2Phase 3 Interventional

A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

NCT01318434
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
EB-1010 25mg BID, SSRI Active, EB-1010 50mg BID, Placebo
Drug
Lead sponsor
Euthymics BioScience, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
43
States / cities
Arcadia, California • Beverly Hills, California • National City, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 28, 2026, 4:56 PM EDT
Completed Not applicable Interventional Results available

Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders

NCT01947647
View directory record Official record
Conditions
Major Depressive Disorder, Persistent Depressive Disorder, Posttraumatic Stress Disorder, Panic Disorder, Social Phobia, Specific Phobia, Generalized Anxiety Disorder, Obsessive Compulsive Disorder
Interventions
Transdiagnostic Behavior Therapy, Behavioral Activation Therapy
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 28, 2026, 4:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)

NCT02433093
View directory record Official record
Conditions
Major Depressive Disorder, Healthy Volunteer
Interventions
Basimglurant, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 28, 2026, 4:56 PM EDT
Terminated Not applicable Interventional Results available

Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)

NCT01426516
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Genecept Assay
Device
Lead sponsor
Genomind, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 28, 2026, 4:56 PM EDT
Completed Phase 4 Interventional Results available

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

NCT05859698
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Interventions
Valbenazine
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
18
States / cities
Bryant, Arkansas • Anaheim, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 28, 2026, 4:56 PM EDT
Recruiting Not applicable Interventional

Mindful Self-compassion for Anxiety and Depression: Impact of Delivery Method

NCT07028216
View directory record Official record
Conditions
Anxiety Disorders, Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Agoraphobia, Major Depressive Disorder, Persistent Depressive Disorder (Dysthymia)
Interventions
Mindful Self-Compassion
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 28, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)

NCT01360632
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions
OPC-34712 + ADT, Placebo + ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
52
States / cities
Birmingham, Alabama • Costa Mesa, California • Glendale, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 28, 2026, 4:56 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)

NCT04855747
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
REL-1017, Placebo
Drug
Lead sponsor
Levomecor Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
70
States / cities
Homewood, Alabama • Chandler, Arizona • Phoenix, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 28, 2026, 4:56 PM EDT
Completed Phase 4 Interventional Results available

Depressed Mood Improvement Through Nicotine Dosing (Depressed MIND Study)

NCT02816138
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Nicotine
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 28, 2026, 4:56 PM EDT
Recruiting Not applicable Interventional

IMST for Dementia Risk Reduction

NCT07349706
View directory record Official record
Conditions
Systolic Blood Pressure, Blood Pressure, Depression - Major Depressive Disorder, Anxiety, Sleep Quality, Physical Function, Cognitive Function
Interventions
Inspiratory Muscle Strength Training High-Resistance, Inspiratory Muscle Strength Training Low-Resistance
Device
Lead sponsor
Florida State University
Other
Eligibility
60 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 28, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression

NCT02285504
View directory record Official record
Conditions
Postpartum Depression
Interventions
SAGE-547
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 28, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study

NCT02218008
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • Colton, California • Garden Grove, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 28, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

NCT01371708
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
DVS SR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
35
States / cities
Birmingham, Alabama • Tucson, Arizona • Imperial, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 28, 2026, 4:56 PM EDT
Completed Not applicable Interventional Results available

Study to Evaluate Treatment Effects Associated With the NeuroStar SoftStart Treatment Feature

NCT05535062
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
repetitive Transcranial Magnetic Stimulation
Device
Lead sponsor
Neuronetics
Other
Eligibility
22 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 28, 2026, 4:56 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Sensory Synchronized Imaging and Neuromodulation

NCT06548113
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
TMS
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Test a New Drug to Treat Major Depression

NCT00976560
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
GW856553, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Hoffman Estates, Illinois • Park Ridge, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 28, 2026, 4:56 PM EDT
Completed Phase 4 Interventional

Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.

NCT00208715
View directory record Official record
Conditions
Major Depression, Mental Health
Interventions
Provigil
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
4
States / cities
Stanford, California • Atlanta, Georgia • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 28, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder

NCT01447576
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ADT, OPC-34712
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,036 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
32
States / cities
Arcadia, California • San Diego, California • Sherman Oaks, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 28, 2026, 4:56 PM EDT
Terminated Phase 3 Interventional

Study to Assess the Safety and Effectiveness of NMRA-335140-501

NCT06029439
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NMRA-335140
Drug
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
904 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
126
States / cities
Huntsville, Alabama • Phoenix, Arizona • Bentonville, Arkansas + 94 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 28, 2026, 4:56 PM EDT